Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry

Authors: Skinner, Michael A; Laidlaw, Stephen M; Eldaghayes, Ibrahim; Kaiser, Pete; Cottingham, Matthew G

Source: Expert Review of Vaccines, 1 February 2005, vol. 4, no. 1, pp. 63-76(14)


Buy & download fulltext article:

The full text article is temporarily unavailable.

We apologise for the inconvenience. Please try again later.


Live vaccines against fowlpox virus, which causes moderate pathology in poultry and is the type species of the Avipoxvirus genus, were developed in the 1920s. Development of recombinant fowlpox virus vector vaccines began in the 1980s, for use not only in poultry, but also in mammals including humans. In common with other avipoxviruses, such as canarypox virus, fowlpox virus enters mammalian cells and expresses proteins, but replicates abortively. The use of fowlpox virus as a safe vehicle for expression of foreign antigens and host immunomodulators, is being evaluated in numerous clinical trials of vaccines against cancer, malaria, tuberculosis and AIDS, notably in heterologous prime–boost regimens. In this article, technical approaches to, and issues surrounding, the use of fowlpox virus as a recombinant vaccine vector in poultry and mammals are reviewed.

Keywords: DNA prime–boost vaccination; Newcastle disease virus; avian influenza virus; avipoxviruses; infectious bursal disease virus; interleukin-18; live attenuated vaccine viruses; nonreplicating poxvirus vectors

Document Type: Research Article


Affiliations: Institute for Animal Health, Compton, Newbury, Berkshire, RG20 7NN, UK., Email:

Publication date: February 1, 2005

Related content


Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page